Reneuron Share Discussion Threads

[xow98] 18/6/2019 08:06

Would they not want to release something prior to to meeting to get the analysts interested?

[jensonbensonjohnson] 18/6/2019 07:53

Sounds like it, doesn't it. Three weeks Thursday it is, then.

[philh75] 18/6/2019 07:42

Is that RNS code for, "there won't be any more news until after the results"

[martinfrench] 15/6/2019 18:22

Was referring to previous non existent communication, or at very least highlighting the science

[rayrac] 15/6/2019 09:00

What do you want them to communicate martin..news before the facts?

Not on, is it?

[martinfrench] 14/6/2019 20:05

Would have been very surprised if we had won communicator of the year.

Maybe with all the fund types on the panel it wasnt just zcientic break through but commercial. Well here's hoping

[bantam175] 14/6/2019 13:36

Sry. Left off a zero :-/

[bantam175] 14/6/2019 13:35

This hasn't really gained anything. Just recouped the fall caused by the share consolidation. They were usually around the 3p mark pre-consolidation.

There were estimates of 30p back then so on that basis these should go to 300ish.

Don't bet the house. I think we all know it won't.

Any up from here would be welcome though. Seems to be dithering around.

All imho dyor etc etc.

[martinfrench] 14/6/2019 12:46

would be nice to form an inverse head and shoulders pattern at £3 Rene.....then lift off on next results.

well thats my plan anyway.

sold 12000 centamin (just a trading move) so have some dry powder ready...

[rayrac] 14/6/2019 12:08

In the spotlight!

[rayrac] 14/6/2019 12:08

Yeh, we got you martin. ;)

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is delighted to announce that it has won the 'Breakthrough of the Year' award at last night's 2019 European Mediscience Awards in London.

This award underlines the strong clinical development and commercial progress ReNeuron has made over the past year. This includes positive data from the ongoing Phase 1/2a clinical trial in Retinitis Pigmentosa and the signing of an exclusive licence agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. for the development, manufacture and commercialisation of ReNeuron's CTX and hRPC cell therapy programmes in the People's Republic of China.

Olav Hellebø, Chief Executive Officer of ReNeuron, commented:

"We are delighted to have been awarded the Breakthrough of the Year award at the 2019 European Mediscience Awards. We are greatly encouraged by the progress we have made with our cell therapy clinical development programmes for retinitis pigmentosa and stroke disability over the past year and look forward to continuing to advance our clinical and business development activities in the months ahead."

The European Mediscience Awards is one of the largest annual gathering of private and publicly quoted healthcare, biotech and life sciences companies in Europe. It celebrates the best in the sector and highlights the achievements of individuals and companies operating within it.

[martinfrench] 14/6/2019 11:52

chance not change

[martinfrench] 14/6/2019 11:50

and as we know....when this goes it REALLY goes.

[martinfrench] 14/6/2019 11:50

totally agree blond,

can you imagine how embarassing it would be to have failed RP after this?

join the dots and the excitement, i would think only 5% change next cohort not up to scratch

[martinfrench] 13/6/2019 17:14

apart from rene, the rise we are all well aware of, looks pretty dire and rene still > 50% down on his buy price!

[martinfrench] 13/6/2019 17:13

care of the wpct board....

Woodentops health care performance, OMG!!

1 month 6 months
E-Therapeutics -24% -75%
Circassia -35% -69%
Autolus -33% -54%
Verseon NA -54%
Theravance -37% -41%
Mereo Biopharma -18% -38%
Nucana Biomed -22% -33%
Alkermes -17% -33%
IP Group -20% -30%
Biogen -2% -29%
4D Pharma -18% -25%
Prothena -17% -24%
Arix Bioscience -10% -20%
Horizon Discovery Group -24% -18%
Agios -9% -10%
Northwest Biotherapeutics -18% -7%
Allied Minds +19% +6%
Evofem Biosciences +41% +82%
Reneuron -17% +375%

[hollywood6] 13/6/2019 16:26

Read the presentations

[stewart_25] 13/6/2019 14:57

Good question JBJ - Also would like to know what hollywood6 is referring to ...

[jensonbensonjohnson] 13/6/2019 13:27

To which quotes do you refer?

[hollywood6] 13/6/2019 13:06

I am considering getting back in but I was not filled with confidence by the patient quotes in the RP trial

[jensonbensonjohnson] 13/6/2019 10:16

Well it's feasible for them to wait until the initial carnage abates!

Year end results on Thursday 11 July 2019 though; they can't move that date.